Proactive Investors - Run By Investors For Investors

Emerald Health Therapeutics' joint venture receives TSX Venture Exchange conditional approval

The Vancouver-based company will invest C$5 million for a 51% equity stake in Emerald Health Naturals
handshake
Emerald Health Therapeutics will invest C$5 million for a 51% equity stake in the joint venture, known as Emerald Health Naturals

Emerald Health Therapeutics Inc (CVE:EMH, OTCMKTS:EMHTF) said Monday that it has received conditional approval from the TSX Venture Exchange for its joint venture with San Diego-based Emerald Health Bioceuticals (EHB).

Vancouver-based Emerald Health Therapeutics will invest C$5 million for a 51% equity stake in the joint venture, known as Emerald Health Naturals.

READ: Emerald Health Therapeutics files 17 US patent applications to protect product line

EHB will grant the joint venture exclusive Canadian distribution rights to its product line in exchange for 49% equity ownership. EHB’s products consist of nutritional supplements that use non-cannabis, non-psychoactive plant-based bioactive compounds to support the body’s endocannabinoid system of neurotransmitters that bind to cannabinoid receptors.

Market research commissioned by Emerald Health Therapeutics has found that about 60% of legal cannabis users also use natural health products.

Shares of Emerald Health Therapeutics slipped C$0.18 to C$3.74 in Canada. They slipped US$0.16 to US$2.84 in OTC trading.


Contact Dennis Fitzgerald at [email protected]
 

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full EMH profile View Profile

Emerald Health Therapeutics Inc Timeline

Related Articles

Surgery
February 20 2019
Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled last year to £11.6mln, up from £5.2mln a year earlier
Cyrptocurrencies
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
Cancer cells
February 12 2019
The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use